Pluristem Therapeutics Inc.
PLXProtalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
10dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PLX Earnings Report
EPS Est: $-0.01 | FQ end 2026-06
How PLX's past catalysts played out
PLX-PAD
Hip Fracture
PLX-PAD Low dose
Intermittent Claudication
150M PLX-PAD
Total Hip Arthroplasty
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PLX-PAD | Phase 3 | Hip Fracture | - | - |
PLX-PAD Low dose | Phase 2 | Intermittent Claudication | - | - |
150M PLX-PAD | Phase 2 | Total Hip Arthroplasty | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pluristem Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Pluristem Therapeutics Inc.'s (PLX) pipeline across Phase 3, Phase 2. Its lead program is PLX-PAD (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pluristem Therapeutics Inc.'s next FDA catalyst?→
Pluristem Therapeutics Inc.'s (PLX) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PLX biotech catalysts?→
Add PLX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pluristem Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.